---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-141085"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:35:09.485663+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants

## Summary
- Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.
- Underwriters granted 30-day option to purchase additional 1.53M shares; expected close June 16, 2025.
- Net proceeds including option exercise expected ~$216.1M, for working capital and general corporate purposes.
- Joint book-runners: Jefferies, Goldman Sachs, TD Cowen, Mizuho; LifeSci Capital as lead manager.

## SEC filing metadata
- accession: 0001193125-25-141085
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312525141085/0001193125-25-141085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312525141085/d150245d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-141085
- JSON: https://secwatch.observer/filing/0001193125-25-141085.json
- Plain text: https://secwatch.observer/filing/0001193125-25-141085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.